InflaRx N.V. reported preclinical data on May 4, 2026, showing that izicopan, a new drug, has a low level of reactive metabolite formation, indicating potential safety advantages over alternatives like avacopan. This suggests a differentiated profile for izicopan in the C5aR inhibitor class, which may indicate lower safety risks.